1. Home
  2. SNFCA vs GALT Comparison

SNFCA vs GALT Comparison

Compare SNFCA & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Security National Financial Corporation

SNFCA

Security National Financial Corporation

N/A

Current Price

$9.35

Market Cap

234.1M

Sector

Finance

ML Signal

N/A

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

HOLD

Current Price

$6.54

Market Cap

232.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNFCA
GALT
Founded
1965
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
234.1M
232.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SNFCA
GALT
Price
$9.35
$6.54
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$6.00
AVG Volume (30 Days)
31.8K
465.8K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.74
N/A
Revenue
$340,876,482.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.19
N/A
Revenue Growth
3.25
N/A
52 Week Low
$7.32
$0.73
52 Week High
$12.83
$6.66

Technical Indicators

Market Signals
Indicator
SNFCA
GALT
Relative Strength Index (RSI) 72.54 61.80
Support Level $8.52 $5.10
Resistance Level $8.82 $6.32
Average True Range (ATR) 0.26 0.56
MACD 0.08 0.04
Stochastic Oscillator 100.00 93.06

Price Performance

Historical Comparison
SNFCA
GALT

About SNFCA Security National Financial Corporation

Security National Financial Corp is engaged in the life insurance, cemetery and mortuary, and mortgage loan businesses. The life insurance segment is engaged in the business of selling and servicing selected lines of life insurance, annuity products, and accident and health insurance. Its cemetery and mortuary segment consists of approximately seven mortuaries and five cemeteries in the state of Utah and a cemetery in the state of California. The mortgage loan segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and real estate projects. Geographically, all the business activity is functioned through the region of the USA and it derives the majority of revenue from Mortgage segment.

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: